The body of someone with chronic insomnia is, in a sense, always braced. Heart rate a touch high, mind refusing to idle, muscles never quite letting go, even at 3am when nothing is happening and nothing needs to. Sleep scientists have a name for this perpetual readiness: hyperarousal. And it now looks like the lever a self-guided app pulls when it quietly improves not just sleep, but mood and worry too.
That, at least, is what a new analysis of a German insomnia therapy suggests. The therapy is called somnovia, and the question the researchers asked was deceptively simple: when it works, what exactly is it fixing first?
Most trials would never answer that. They lump every symptom into a single score, tally it before and after, and report whether the number dropped. Useful, sure, but it flattens everything. Difficulty falling asleep and daytime exhaustion get treated as interchangeable, even though they are clearly different beasts that may respond to treatment at quite different speeds. Linda Betz and her colleagues wanted to pull that lump apart.
So they went back to a completed randomized trial of 290 adults with chronic insomnia, roughly three-quarters of them women, average age around 50. Half had used somnovia on top of their usual care; half had usual care alone.
Then they ran something called network intervention analysis. Rather than a single before-and-after number, the method maps each individual symptom, sleep complaints, depressive symptoms, anxiety symptoms, as a node in a web, with the lines between them showing which symptoms move together. Crucially, it can also show which symptoms the treatment touches directly, and which only shift because their neighbours did.
The picture at three months was strikingly narrow. somnovia was tugging hardest on a small cluster: difficulty relaxing, dissatisfaction with sleep, worry about sleep, and to a lesser degree a kind of restless physical agitation. Everything else, the better mood, the lower anxiety, seemed to come along indirectly, downstream of those few.
The Knot Beneath the Sleeplessness
What links that cluster is arousal. Not the racy kind, the clinical kind. Worry about sleep and dissatisfaction with it are the cognitive, churning end of the spectrum; the difficulty relaxing and the bodily restlessness sit at the physiological end. somnovia, which delivers the standard toolkit of cognitive behavioural therapy for insomnia (sleep restriction, stimulus control, relaxation work, and techniques for interrupting the 2am spiral of catastrophic thoughts) appears to lean on both ends at once. The effect, as Betz puts it, is that the programme primarily targets a central transdiagnostic process: hyperarousal
. Loosen that, and the vicious loop of frustration and vigilance that keeps insomnia spinning starts, perhaps, to slacken.
Then time did something interesting. By six months, the tidy little cluster had spread.
The treatment’s fingerprints were now smudged across the wider network, reaching fatigue, excessive worry, appetite. Dissatisfaction with sleep and sleep-related worry were still the strongest links, but the influence had diffused outward. The researchers read this not as the therapy fading but as its benefit becoming embedded, soaking into the whole symptom system rather than sitting on a few complaints. As they describe it, the early gains in core arousal symptoms ripple along the connections to their neighbours, and the neighbours’ neighbours, until the improvement is everywhere and nowhere in particular.
One Lever, Many Symptoms
Here is why that matters well beyond a single app. Insomnia is not just an unpleasant thing in its own right; it is a known predictor of depression and anxiety, a thread running through dozens of mental health conditions. If hyperarousal really is the shared upstream knot, then untangling it early, with something as cheap and scalable as a website, could in principle head off trouble that would otherwise surface later as something darker. That is a big “if,” and worth keeping in view. The depression and anxiety effects here were knock-on, not direct, and some of the later, weaker links in the network were a bit wobbly, the kind of finding that wants replicating before anyone gets carried away.
One more thing worth flagging: somnovia is made by GAIA, the company that also funded this work and pays two of the authors. It is already prescribable in Germany, listed in the national directory of digital health apps, with the cost picked up by statutory insurers, which makes the question of how, and how well, it actually works rather more than academic. The next step is teasing apart which bits of the programme do the loosening, and whether the same upstream-knot logic holds for other digital therapies built on the same bones.
For now, the takeaway is quietly radical. Treat the sleep, and you may be treating a good deal more than the sleep.
Source: Betz et al., Behaviour Research and Therapy (2026), DOI 10.1016/j.brat.2026.105075
Frequently Asked Questions
Why would an insomnia app affect depression and anxiety at all?
Because the three conditions appear to share an underlying driver: hyperarousal, a state of being mentally and physically over-keyed. The analysis suggests that when the therapy calms that arousal to help with sleep, the benefit travels along to connected symptoms of low mood and worry over time, rather than the app treating depression head-on. It is sleep as an upstream lever, not a cure-all.
How does network intervention analysis actually work?
Instead of collapsing all of a person’s symptoms into one score, it treats each symptom as a point in a web and maps which ones move together and which the treatment touches first. That lets researchers separate symptoms changed directly by the therapy from those that only improve because a connected symptom got better. It is a way of seeing the order in which recovery unfolds.
Is a self-guided app really as good as seeing a therapist for insomnia?
Meta-analyses suggest digital cognitive behavioural therapy for insomnia reaches efficacy broadly comparable to face-to-face treatment, which matters because trained therapists are in short supply and waiting lists are long. somnovia is fully self-guided, with no therapist contact, and most users in the trial finished the whole programme. Whether it suits everyone is a separate question worth asking your doctor.
Should I trust a study funded by the company that sells the product?
It is a fair flag. The developer funded the work and employs two authors, which is disclosed, and the underlying trial was randomized and registered in advance, which tightens the case. Still, independent replication is the thing that would settle it, and that has not happened yet.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.